Neutralizing monoclonal antibodies for resisting H7N9 influenza virus

A technology of antibody and carrier, applied in the direction of antiviral agent, antiviral immunoglobulin, antibody, etc.

Inactive Publication Date: 2018-11-13
INST PASTEUR OF SHANGHAI CHINESE ACADEMY OF SCI
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no effective vaccine against H7N9 avian influenza virus on the market

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Neutralizing monoclonal antibodies for resisting H7N9 influenza virus
  • Neutralizing monoclonal antibodies for resisting H7N9 influenza virus
  • Neutralizing monoclonal antibodies for resisting H7N9 influenza virus

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0152] Preparation of monoclonal antibodies

[0153]Antibodies of the present invention can be prepared by various techniques known to those skilled in the art. For example, an antigen of the invention may be administered to an animal to induce the production of monoclonal antibodies. For monoclonal antibodies, hybridoma technology can be utilized to prepare (see Kohler et al., Nature 256; 495, 1975; Kohler et al., Eur.J.Immunol.6:511, 1976; Kohler et al., Eur.J.Immunol. 6:292, 1976; Hammerling et al., In Monoclonal Antibodies and T Cell Hybridomas, Elsevier, N.Y., 1981) or can be prepared by recombinant DNA method (US Patent No. 4,816,567).

[0154] Representative myeloma cells are those that fuse efficiently, support stable high-level production of antibody by selected antibody-producing cells, and are sensitive to culture medium (HAT medium matrix), including myeloma cell lines, such as murine Myeloma cell lines, including those derived from MOPC-21 and MPC-11 mouse tumor...

Embodiment 2

[0167] Mouse serum titer after embodiment 2 immunization

[0168] 2.1 Mice immunization, screening and serum neutralization activity evaluation

[0169] see figure 2 , take conventional immunization methods, and immunize mice. Five BALB / c female mice of 6-8 weeks in each group were intramuscularly injected with 100ug / mouse of the constructed HA DNA vaccine. Three consecutive immunizations, each with an interval of two weeks. Ten days after the third immunization, blood was collected from the orbit of the mice, the serum was separated, and the titer of the serum was determined. The mouse with the highest titer was selected for booster immunization, that is, 100 μg of HA protein was mixed with an equal volume of Freund's complete adjuvant 2 weeks after the third immunization, and the mice were immunized by subcutaneous injection after complete emulsification. After 3 days, recall stimulation was performed. Three days later, the mouse spleen was taken for cell fusion. At t...

Embodiment 3

[0174] Embodiment 3 monoclonal hybridoma cell obtains

[0175] 3.1 Preparation and screening of mouse hybridomas to obtain neutralizing antibody cell lines

[0176] According to the results of ELISA detection, the mouse with the highest antibody titer was selected as the immune cell donor. Mouse splenocytes were mixed with myeloma cells screened by 8-azaguanine, fused under PEG4000 treatment, and then added with HAT for screening. After the unfused cells died completely and the hybridoma clones grew out, the culture supernatant was collected , Antibody detection by ELISA. Select the antibody-positive and high-titer cells, perform limiting dilution, and pick out monoclonal cells. Take BALB / c mice, inject 0.5mL pristane (pristane) intraperitoneally, and then inject 0.5mL intraperitoneally after 7-10 days, the obtained monoclonal 1×10 6 Hybridoma cells, after about 10 days to 20 days, the mice grow ascites, and the ascites containing monoclonal antibodies can be obtained by ha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses neutralizing monoclonal antibodies for resisting the H7N9 influenza virus and particularly discloses two monoclonal antibodies aiming at the H7N9 influenza virus. The antibodies has evident combining activity to H7N9 influenza virus antigens.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular, the invention relates to two kinds of neutralizing monoclonal antibodies against H7N9 influenza virus. Background technique [0002] Influenza viruses belong to the Orthomyxoviridae family and are enveloped, single-stranded, negative-sense RNA viruses. Influenza viruses can be divided into three types: A, B, and C. Among them, influenza A virus has many hosts, is widespread, and has strong pathogenicity. It is the main type that causes influenza. According to the antigenicity of the surface proteins hemagglutinin (HA) and neuraminidase (NA), influenza A viruses are divided into 18 HA subtypes and 11 NA subtypes. According to the difference of HA antigen, it can be divided into two evolutionary groups. [0003] The genome of influenza virus is divided into 8 segments, encoding more than 10 proteins. They play an important role in various processes such as virus infection, replication, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13A61K39/395A61P31/16G01N33/68G01N33/569
CPCC07K16/1018A61K2039/505C07K2317/24C07K2317/565C07K2317/76
Inventor 孙兵高秀孙晓玉卢晓凌志洋
Owner INST PASTEUR OF SHANGHAI CHINESE ACADEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap